Adult T-cell leukemia (ATL) is a leukemia of mature peripheral T lymphocytes associated with human T-lymphotropic virus type I (HTLV-I). We previously reported that all-trans retinoic acid (ATRA) inhibited cell growth and induced apoptosis in HTLV-I ( þ ) T-cell lines as well as fresh ATL cells obtained from ATL patients. [1] [2] [3] [4] Tsukasaki et al 5 reported an interesting case in which ATRA induced complete remission for a patient with double hematological malignancies, acute promyelocytic leukemia and ATL. ATL is characterized by infiltration of various tissues by circulating ATL cells. Especially, skin lesions occur in 50% of ATL patients. In this study, we observed the effects of ATRA on skin involvement in ATL patients.
Eight patients with ATL (two cases acute type, five chronic type and one smoldering type) were selected for this study. Cutaneous lesions included erythematous plaques, papules, nodules, erythroderma and tumors. Patients were scheduled to receive oral ATRA 45 mg/m 2 daily. During treatment with ATRA, there was no chemotherapy or glucocorticoid therapy administered. Patients were monitored for safety and antitumor effect by regular physical examination and laboratory studies including complete and differential blood count and standard chemistry performed at the baseline and repeated at weeks 1, 2, 3 and 4. Skin biopsy was carried out before and after treatment with ATRA. Complete response required all skin eruptions coming macroscopically negative. ATRA was effective for skin involvement in six patients. A typical case is discussed as follows: a 42-year-old Japanese woman was referred to our hospital because of skin eruption with chronic ATL. After detection of proviral DNA in the skin by Southern blot analysis, ATRA (60 mg/day) was administered. The skin biopsy exhibited dense lymphoid infiltrates with atypical cytological features in the dermis. The infiltrate was composed mainly of medium to large cells with irregular nuclei. Neoplastic cells showed mild epidermotropism. There was a clinical and histological improvement after ATRA therapy was given for 4 weeks (Figure 1a) . Furthermore, proviral DNA for HTLV-I by Southern blot analysis in skin became negative after treatment with ATRA (Figure 1b) . These results indicated that ATRA may be a useful agent for skin involvement of ATL. Adverse effects were seen in six of eight patients, these effects were temporally and generally mild (three cases of headache, two cases of dry skin and one case of skin pigmentation). This confirms that as it has been reported ATRA only shows toxicities in a few cases. We had two cases that did not respond to ATRA, indicative of ATRA-resistant cases. Differences between good responders and resistant cases should be investigated, including the mechanism of ATRA action for skin involvement.
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Figure 1
Effects of ATRA for skin involvement. (a) Skin biopsy specimen (hematoxylin and eosin; original magnification Â 40) before and after ATRA treatment. (b) Proviral DNA by Southern blot analysis before and after ATRA treatment. Two bands of slightly differing intensity are shown after EcoRI digestion from skin sample before ATRA therapy. After ATRA therapy, there were no integration bands detected. M: molecular marker, E: EcoRI, P: PstI.
